Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Zacks Investment Research to Sell

Milestone Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Milestone Pharmaceuticals Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Milestone Pharmaceuticals traded down -$0.02 on Wednesday, reaching $5.67. 0 shares of the stock traded hands, compared to its average volume of 29966. Shares of Milestone Pharmaceuticals were trading at $5.67 on Wednesday. The firm’s 50 day moving average is $5.70 and its 200 day moving average is $6.18.Milestone Pharmaceuticals has a 12 month low of $5.64 and a 12 month high of $9.03. While on yearly highs and lows, Milestone Pharmaceuticals’s today has traded high as $5.85 and has touched $5.64 on the downward trend. See More Analyst Rating at: RATING

Milestone Pharmaceuticals Earnings and What to expect: 

Milestone Pharmaceuticals last released its quarterly earnings results on August 11th, 2021. The reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.28. The company earned $15 million during the quarter. Milestone Pharmaceuticals has generated ($1.70) earnings per share over the last year (($0.91) diluted earnings per share). Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.10) to ($1.61) per share. Milestone Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 12th, 2021 based off prior year’s report dates.

Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.10) to ($1.61) per share. The P/E ratio of Milestone Pharmaceuticals is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Milestone Pharmaceuticals is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Milestone Pharmaceuticals has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Milestone Pharmaceuticals (NASDAQ:MIST) Moving Average Technical Analysis

5 day Moving Average is $5.70 And 5 day price change is -$0.07 (-1.22%)  with average volume for 5 day average is 17,220. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $5.69 and 20 day price change is -$0.14 (-2.41%) and average 20 day moving volume is 19,145. 50 day moving average is $5.70  and 50 day price change is $0.25 ( 4.62%)  and with average volume for 50 days is : 28,812. 200 day moving average is $6.18  and 200 day price change is -$1.08 (-16.02%)  and with average volume for 200 days is : 65,055.

Other owners latest trading in Milestone Pharmaceuticals :

  • On 8/23/2021 shares held by Morgan Stanley were 885,199 which equates to market value of $4.87M and appx 0.00% owners of Milestone Pharmaceuticals
  • On 8/18/2021 shares held by Ikarian Capital LLC were 1,980,400 which equates to market value of $10.89M and appx 0.90% owners of Milestone Pharmaceuticals
  • On 8/17/2021 shares held by Boothbay Fund Management LLC were 224,758 which equates to market value of $1.24M and appx 0.00% owners of Milestone Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 67.49% for Milestone Pharmaceuticals

See More Analyst Rating at: RATING